Infinium Pharmachem Ltd (INFINIUM) News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{
  "main_header": {
    "sid": 1003829,
    "name": "Infinium Pharma",
    "stock_name": "Infinium Pharma",
    "full_name": "Infinium Pharmachem Ltd",
    "name_url": "stocks-analysis/infinium-pharma",
    "exchange": 1,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "239.80",
    "chg": -2.2,
    "chgp": "-0.91%",
    "dir": -1,
    "prev_price": "242.00",
    "mcapval": "374.00 Cr",
    "mcap": "Micro Cap",
    "scripcode": "",
    "symbol": "INFINIUM",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "indexname": "",
    "isin": "INE0MRE01011",
    "curr_date": "Dec 05",
    "curr_time": "",
    "bse_nse_vol": 500,
    "exc_status": "Active",
    "traded_date": "Dec 05, 2025",
    "traded_date_str": "2025 12 05",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/infinium-pharma-1003829-1&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Is Infinium Pharma overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-infinium-pharma-overvalued-or-undervalued-3713744",
        "imagepath": "",
        "date": "2025-11-19 08:12:26",
        "description": "As of 18 November 2025, the valuation grade for Infinium Pharma has moved from attractive to fair, indicating a shift in its perceived market value. The company is currently fairly valued, with a PE ratio of 45.72, an EV to EBITDA ratio of 24.71, and a ROE of 7.68%. In comparison to its peers, Sun Pharma has a PE ratio of 36.56 and is considered expensive, while Cipla, which is rated attractive, has a significantly lower PE ratio of 22.49.\n\nDespite the fair valuation, Infinium Pharma's recent stock performance has been underwhelming, with a year-to-date return of -17.14%, contrasting sharply with the Sensex's gain of 9.58% over the same period. This underperformance, coupled with high valuation ratios, suggests that while the company is not overvalued, it may not present an attractive investment opportunity at this time...."
      },
      {
        "title": "Is Infinium Pharma overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-infinium-pharma-overvalued-or-undervalued-3710168",
        "imagepath": "",
        "date": "2025-11-18 08:29:21",
        "description": "As of 17 November 2025, Infinium Pharma's valuation grade has moved from very expensive to attractive, indicating a significant shift in its perceived value. The company is currently assessed as undervalued, especially when compared to its peers in the pharmaceuticals and biotechnology sector. Key ratios include a PE ratio of 44.28, an EV to EBITDA of 23.90, and a ROE of 7.68%. \n\nIn terms of peer comparison, Infinium Pharma's PE ratio is notably higher than Sun Pharma's 36.69 and significantly lower than Divi's Lab's 69.78, which reflects a more favorable valuation position. Additionally, while Infinium's PEG ratio stands at 0.00, indicating potential for growth, peers like Cipla and Dr. Reddy's Labs have PEG ratios of 1.28 and 2.22, respectively, suggesting that Infinium may offer better value relative to its growth prospects. The recent performance of Infinium Pharma, with a year-to-date return of -19.74%..."
      },
      {
        "title": "Why is Infinium Pharma falling/rising?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/why-is-infinium-pharma-fallingrising-3709428",
        "imagepath": "",
        "date": "2025-11-17 23:59:23",
        "description": "As of 17-Nov, Infinium Pharmachem Ltd's stock price is currently at 240.70, reflecting a decrease of 9.4 points or 3.76%. The stock has underperformed its sector by 4.04% today and is trading below its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages. Additionally, there has been a significant decline in investor participation, with delivery volume dropping by 53.13% against the 5-day average. Over the past week, the stock has seen a return of -7.42%, and year-to-date, it has declined by 19.74%, indicating a consistent downward trend without any available positive factors to counterbalance this performance.\n\nBroader Market Context: In contrast, the benchmark Sensex has shown a positive return of 1.72% over the past week and 10.02% year-to-date, highlighting a stark difference in performance between Infinium Pharmachem Ltd and the broader market. This divergence suggests that while the market is e..."
      },
      {
        "title": "How has been the historical performance of Infinium Pharma?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/how-has-been-the-historical-performance-of-infinium-pharma-3699779",
        "imagepath": "",
        "date": "2025-11-13 23:50:15",
        "description": "Answer:\nThe historical performance of Infinium Pharma shows a consistent growth trend in net sales and profits over the past four years.\n\nBreakdown:\nInfinium Pharma's net sales have increased from 99.12 Cr in March 2022 to 155.71 Cr in March 2025, reflecting a steady upward trajectory. Total operating income followed a similar pattern, rising from 99.12 Cr to 155.71 Cr in the same period. However, total expenditure also grew, from 89.09 Cr in March 2022 to 139.29 Cr in March 2025, impacting operating profit which peaked at 20.07 Cr in March 2024 but fell to 18.54 Cr in March 2025. Profit before tax showed fluctuations, reaching 11.57 Cr in March 2025 after being 15.21 Cr in March 2024. The profit after tax decreased from 11.50 Cr in March 2024 to 7.84 Cr in March 2025. The company's total assets surged from 58.93 Cr in March 2022 to 198.24 Cr in March 2025, while total liabilities also increased significant..."
      },
      {
        "title": "Why is Infinium Pharma falling/rising?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/why-is-infinium-pharma-fallingrising-3691418",
        "imagepath": "",
        "date": "2025-11-12 00:06:58",
        "description": "As of 11-Nov, Infinium Pharmachem Ltd is experiencing a price increase, currently at 269.40, reflecting a rise of 9.4 or 3.62%. The stock has shown positive performance today, outperforming its sector by 3.9%. Additionally, it is trading above its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating a strong upward trend. However, there is a notable decline in investor participation, with delivery volume dropping by 93.79% compared to the 5-day average. Over the past week, the stock has gained 2.05%, and over the past month, it has risen by 5.03%, although it remains down 10.17% year-to-date and 18.82% over the past year.\n\nIn the broader market context, the Sensex has increased by 0.38% over the past week and 1.62% over the past month, indicating that Infinium's short-term performance is significantly better than the benchmark. Despite the stock's recent gains, its year-to-date and one-ye..."
      },
      {
        "title": "Is Infinium Pharma overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-infinium-pharma-overvalued-or-undervalued-3597272",
        "imagepath": "",
        "date": "2025-10-07 08:07:30",
        "description": "As of 6 October 2025, the valuation grade for Infinium Pharma has moved from fair to very expensive, indicating a significant shift in its market perception. The company is currently deemed overvalued based on its high valuation ratios, including a PE ratio of 45.35, an EV to EBITDA of 26.13, and a Price to Book Value of 3.63. These figures suggest that investors are paying a premium for the stock relative to its earnings and book value.\n\nIn comparison to its peers, Infinium Pharma's valuation stands out as particularly high. For instance, Sun Pharma has a PE ratio of 34.56 and an EV to EBITDA of 23.42, while Cipla offers a more attractive valuation with a PE of 22.72 and an EV to EBITDA of 15.97. This discrepancy highlights that Infinium Pharma is not only overvalued relative to its immediate competitors but also underperforms in terms of returns, with a year-to-date stock return of -17.81% compared to the..."
      },
      {
        "title": "Is Infinium Pharma overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-infinium-pharma-overvalued-or-undervalued-3569243",
        "imagepath": "",
        "date": "2025-09-25 08:04:35",
        "description": "As of 24 September 2025, Infinium Pharma's valuation grade has moved from attractive to fair, indicating a shift in its market perception. The company is currently fairly valued, with a PE ratio of 46.46, an EV to EBITDA of 25.94, and a ROE of 14.66%. In comparison to its peers, Sun Pharma is considered expensive with a PE of 34.03, while Cipla is attractive at a PE of 22.99, highlighting how Infinium Pharma's valuation stands relative to the broader market.\n\nDespite its fair valuation, Infinium Pharma has underperformed against the Sensex, with a year-to-date return of -15.81% compared to the Sensex's positive return of 5.97%. This underperformance, coupled with its high valuation ratios, suggests that while the company is not overvalued, it may face challenges in justifying its current price level in the near term...."
      },
      {
        "title": "Why is Infinium Pharma falling/rising?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/why-is-infinium-pharma-fallingrising-3568598",
        "imagepath": "",
        "date": "2025-09-24 23:37:11",
        "description": "As of 24-Sep, Infinium Pharmachem Ltd's stock price is currently at 252.50, reflecting a decrease of 1.0, or 0.39%. The stock has shown a negative performance today, which is in line with the sector. It is trading higher than its 5-day moving averages but lower than its 20-day, 50-day, 100-day, and 200-day moving averages. Additionally, there has been a decline in investor participation, with delivery volume falling by 4.76% against the 5-day average. Over the past week, the stock has decreased by 1.37%, and over the past month, it has fallen by 5.78%. Year-to-date, the stock has dropped 15.81%, and over the past year, it has seen a significant decline of 28.77%. There are no available positive or negative factors to provide further context on the stock's recent movement.\n\nBroader market context indicates that the Sensex has experienced a decline of 1.08% over the past week, which is slightly better than In..."
      },
      {
        "title": "Is Infinium Pharma overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-infinium-pharma-overvalued-or-undervalued-3563367",
        "imagepath": "",
        "date": "2025-09-24 08:09:03",
        "description": "As of 23 September 2025, Infinium Pharma's valuation grade has moved from fair to attractive, indicating a more favorable assessment of its market position. The company is currently deemed undervalued, especially when considering its PE ratio of 45.66, an EV to EBITDA of 25.50, and a ROCE of 21.16%. \n\nIn comparison to its peers, Infinium Pharma's valuation stands out, as Sun Pharma has a PE of 34.11 and an EV to EBITDA of 23.09, while Cipla, also rated attractive, has a significantly lower PE of 22.93. Despite a recent decline in stock performance relative to the Sensex, where Infinium Pharma has seen a YTD return of -15.47% compared to the Sensex's 6.45%, the company's strong ratios suggest it is positioned well for future growth...."
      }
    ],
    "total": 71,
    "sid": "1003829",
    "stock_news_url": "https://www.marketsmojo.com/news/infinium-pharmachem-1003829"
  },
  "announcements": "",
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "No <strong>Dividend</strong> history available",
      "data": []
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "",
      "data": [
        {
          "txt": "Infinium Pharmachem Ltd has announced <strong>1:1</strong> bonus issue, ex-date: 13 Sep 23",
          "dt": "2023-09-13",
          "middle_text": "Bonus Alert"
        }
      ]
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Is Infinium Pharma overvalued or undervalued?

2025-11-19 08:12:26

As of 18 November 2025, the valuation grade for Infinium Pharma has moved from attractive to fair, indicating a shift in its perceived market value. The company is currently fairly valued, with a PE ratio of 45.72, an EV to EBITDA ratio of 24.71, and a ROE of 7.68%. In comparison to its peers, Sun Pharma has a PE ratio of 36.56 and is considered expensive, while Cipla, which is rated attractive, has a significantly lower PE ratio of 22.49. Despite the fair valuation, Infinium Pharma's recent stock performance has been underwhelming, with a year-to-date return of -17.14%, contrasting sharply with the Sensex's gain of 9.58% over the same period. This underperformance, coupled with high valuation ratios, suggests that while the company is not overvalued, it may not present an attractive investment opportunity at this time....

Is Infinium Pharma overvalued or undervalued?

2025-11-18 08:29:21

As of 17 November 2025, Infinium Pharma's valuation grade has moved from very expensive to attractive, indicating a significant shift in its perceived value. The company is currently assessed as undervalued, especially when compared to its peers in the pharmaceuticals and biotechnology sector. Key ratios include a PE ratio of 44.28, an EV to EBITDA of 23.90, and a ROE of 7.68%. In terms of peer comparison, Infinium Pharma's PE ratio is notably higher than Sun Pharma's 36.69 and significantly lower than Divi's Lab's 69.78, which reflects a more favorable valuation position. Additionally, while Infinium's PEG ratio stands at 0.00, indicating potential for growth, peers like Cipla and Dr. Reddy's Labs have PEG ratios of 1.28 and 2.22, respectively, suggesting that Infinium may offer better value relative to its growth prospects. The recent performance of Infinium Pharma, with a year-to-date return of -19.74%...

Why is Infinium Pharma falling/rising?

2025-11-17 23:59:23

As of 17-Nov, Infinium Pharmachem Ltd's stock price is currently at 240.70, reflecting a decrease of 9.4 points or 3.76%. The stock has underperformed its sector by 4.04% today and is trading below its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages. Additionally, there has been a significant decline in investor participation, with delivery volume dropping by 53.13% against the 5-day average. Over the past week, the stock has seen a return of -7.42%, and year-to-date, it has declined by 19.74%, indicating a consistent downward trend without any available positive factors to counterbalance this performance. Broader Market Context: In contrast, the benchmark Sensex has shown a positive return of 1.72% over the past week and 10.02% year-to-date, highlighting a stark difference in performance between Infinium Pharmachem Ltd and the broader market. This divergence suggests that while the market is e...

How has been the historical performance of Infinium Pharma?

2025-11-13 23:50:15

Answer: The historical performance of Infinium Pharma shows a consistent growth trend in net sales and profits over the past four years. Breakdown: Infinium Pharma's net sales have increased from 99.12 Cr in March 2022 to 155.71 Cr in March 2025, reflecting a steady upward trajectory. Total operating income followed a similar pattern, rising from 99.12 Cr to 155.71 Cr in the same period. However, total expenditure also grew, from 89.09 Cr in March 2022 to 139.29 Cr in March 2025, impacting operating profit which peaked at 20.07 Cr in March 2024 but fell to 18.54 Cr in March 2025. Profit before tax showed fluctuations, reaching 11.57 Cr in March 2025 after being 15.21 Cr in March 2024. The profit after tax decreased from 11.50 Cr in March 2024 to 7.84 Cr in March 2025. The company's total assets surged from 58.93 Cr in March 2022 to 198.24 Cr in March 2025, while total liabilities also increased significant...

Why is Infinium Pharma falling/rising?

2025-11-12 00:06:58

As of 11-Nov, Infinium Pharmachem Ltd is experiencing a price increase, currently at 269.40, reflecting a rise of 9.4 or 3.62%. The stock has shown positive performance today, outperforming its sector by 3.9%. Additionally, it is trading above its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating a strong upward trend. However, there is a notable decline in investor participation, with delivery volume dropping by 93.79% compared to the 5-day average. Over the past week, the stock has gained 2.05%, and over the past month, it has risen by 5.03%, although it remains down 10.17% year-to-date and 18.82% over the past year. In the broader market context, the Sensex has increased by 0.38% over the past week and 1.62% over the past month, indicating that Infinium's short-term performance is significantly better than the benchmark. Despite the stock's recent gains, its year-to-date and one-ye...

Is Infinium Pharma overvalued or undervalued?

2025-10-07 08:07:30

As of 6 October 2025, the valuation grade for Infinium Pharma has moved from fair to very expensive, indicating a significant shift in its market perception. The company is currently deemed overvalued based on its high valuation ratios, including a PE ratio of 45.35, an EV to EBITDA of 26.13, and a Price to Book Value of 3.63. These figures suggest that investors are paying a premium for the stock relative to its earnings and book value. In comparison to its peers, Infinium Pharma's valuation stands out as particularly high. For instance, Sun Pharma has a PE ratio of 34.56 and an EV to EBITDA of 23.42, while Cipla offers a more attractive valuation with a PE of 22.72 and an EV to EBITDA of 15.97. This discrepancy highlights that Infinium Pharma is not only overvalued relative to its immediate competitors but also underperforms in terms of returns, with a year-to-date stock return of -17.81% compared to the...

Is Infinium Pharma overvalued or undervalued?

2025-09-25 08:04:35

As of 24 September 2025, Infinium Pharma's valuation grade has moved from attractive to fair, indicating a shift in its market perception. The company is currently fairly valued, with a PE ratio of 46.46, an EV to EBITDA of 25.94, and a ROE of 14.66%. In comparison to its peers, Sun Pharma is considered expensive with a PE of 34.03, while Cipla is attractive at a PE of 22.99, highlighting how Infinium Pharma's valuation stands relative to the broader market. Despite its fair valuation, Infinium Pharma has underperformed against the Sensex, with a year-to-date return of -15.81% compared to the Sensex's positive return of 5.97%. This underperformance, coupled with its high valuation ratios, suggests that while the company is not overvalued, it may face challenges in justifying its current price level in the near term....

Why is Infinium Pharma falling/rising?

2025-09-24 23:37:11

As of 24-Sep, Infinium Pharmachem Ltd's stock price is currently at 252.50, reflecting a decrease of 1.0, or 0.39%. The stock has shown a negative performance today, which is in line with the sector. It is trading higher than its 5-day moving averages but lower than its 20-day, 50-day, 100-day, and 200-day moving averages. Additionally, there has been a decline in investor participation, with delivery volume falling by 4.76% against the 5-day average. Over the past week, the stock has decreased by 1.37%, and over the past month, it has fallen by 5.78%. Year-to-date, the stock has dropped 15.81%, and over the past year, it has seen a significant decline of 28.77%. There are no available positive or negative factors to provide further context on the stock's recent movement. Broader market context indicates that the Sensex has experienced a decline of 1.08% over the past week, which is slightly better than In...

Is Infinium Pharma overvalued or undervalued?

2025-09-24 08:09:03

As of 23 September 2025, Infinium Pharma's valuation grade has moved from fair to attractive, indicating a more favorable assessment of its market position. The company is currently deemed undervalued, especially when considering its PE ratio of 45.66, an EV to EBITDA of 25.50, and a ROCE of 21.16%. In comparison to its peers, Infinium Pharma's valuation stands out, as Sun Pharma has a PE of 34.11 and an EV to EBITDA of 23.09, while Cipla, also rated attractive, has a significantly lower PE of 22.93. Despite a recent decline in stock performance relative to the Sensex, where Infinium Pharma has seen a YTD return of -15.47% compared to the Sensex's 6.45%, the company's strong ratios suggest it is positioned well for future growth....

View All News